LTC 002
Alternative Names: LTC-002Latest Information Update: 03 Feb 2023
At a glance
- Originator Leto Laboratories
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer